PRIME: priority medicines

PRIME is a scheme run by the European Medicines Agency (EMA) to enhance support for the development of medicines that target an unmet medical need. This voluntary scheme is based on enhanced interaction and early dialogue with developers of promising medicines, to optimise development plans and speed up evaluation so these medicines can reach...

Last updated:
HumanEarly accessRegulatory and procedural guidanceResearch and development
Guidance for medicine developers and other stakeholders on COVID-19

During the 2020-23 COVID-19 public health emergency, the European Medicines Agency (EMA) provided guidance for medicine developers and pharmaceutical companies to help speed up development and approval for COVID-19 medicines and address regulatory challenges arising from the pandemic.

Last updated:
HumanCOVID-19Clinical trialsCompassionate useRegulatory and procedural guidanceMedicine shortagesResearch and developmentScientific advice
Compassionate use
Last updated:
HumanCompassionate useEarly accessRegulatory and procedural guidanceResearch and development
Adaptive pathways
Last updated:
HumanEarly accessRegulatory and procedural guidanceResearch and development